66 results about "Placental growth factor" patented technology

Disclosed herein are methods for diagnosing pre-eclampsia and eclampsia or a propensity to develop pre-eclampsia or eclampsia by detecting the levels of placental growth factor in a subject.

Disclosed is a method for diagnosing whether a subject suffers from a mild or severe form of liver cirrhosis based on determining the amount of GDF-15 (growth differentiation factor 15), PlGF (placental growth factor), and/or hepatocyte growth factor (HGF) in a sample from the subject and comparing the thus determined amount(s) with a reference amount (reference amounts). The method may further include determining the amount of adiponectin in a sample from the subject, and comparing the amount to a reference amount for adiponectin. Also described is a method to identifying a subject being susceptible to liver transplantation including determining the amount of GDF-15, PlGF, and/or HGF in a sample from the subject and comparing the thus determined amount(s) with a reference amount (reference amounts).

The present invention relates to prevention and treatment of strokes and ischemic diseases and to post-ischemic therapeutic treatment. The invention furthermore relates to the use of a growth factor for treating, more particularly restoring the function of ischemic tissue, in particular muscles such as myocardium and skeletal muscles.

The invention relates to novel markers of vascular inflammation and combinations thereof as diagnostic and prognostic tools in patients with cardiovascular diseases. The markers also act as tools that facilitate the selection of active ingredients for the treatment of such diseases, and finally act as starting points for the treatment of cardiovascular diseases. Furthermore, the invention relates to the creation of an individual risk profile of negative events that are associated with the progression of arteriosclerosis.

The invention discloses a magnetic particle chemiluminescent detection kit for placental growth factor and a preparation method thereof. The kit includes: magnetic particles coupled with placenta growth factor capture antibody, acridinium ester-labeled placenta growth factor detection antibody, placenta growth factor calibrator, chemiluminescence pre-excitation solution A, chemiluminescence excitation solution B and cleaning solution. The kit of the invention uses the magnetic separation chemiluminescence technology as the detection means, and simultaneously combines the acridinium ester labeling technology. The direct chemiluminescence method established by the invention has high sensitivity, strong specificity, accuracy and speed, short detection time and higher accuracy and repeatability of detection results, and the kit can be applied to various luminescence detection instruments.

The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human and mouse secreted stem cell growth factor-like polypeptide. These polynucleotides comprise nucleic acid sequences isolated from cDNA libraries prepared from mouse bone marrow and human fetal liver spleen, ovary, adult brain, lung tumor, spinal cord, cervix, ovary, endothelial cells, umbilical cord, placental, lymphocyte, lung fibroblast, fetal brain, and testis. Other aspects of the invention include vectors containing processes for producing novel human secreted stem cell growth factor-like polypeptides, and antibodies specific for such polypeptides.

The invention discloses a monoclonal antibody of anti-human PIGF (placental growth factor) protein, which can be specifically bonded with human PIGF and block PIGF from joining receptors of the PIGF. The invention further discloses a preparation method of the monoclonal antibody. Besides, the invention discloses an application of the monoclonal antibody in qualitative and quantitative detection to the human PIGF protein. Furthermore, the invention discloses an application of the monoclonal antibody in preparing drugs for treating tumors.

Vascular endothelial growth factor, placenta growth factor or combinations of both including heteodimers are useful in the treatment or prevention of stroke or ischemic diseases in mammals.

The invention provides a novel brain targeting preparation for preventing and treating a neurodegenerative disease. The novel brain targeting preparation comprises effective dose of fusion protein of cell growth factor and TAT (transcriptional activator) cell-penetrating peptide, or fusion protein of the cell growth factor, TAT and a transferrin receptor monoclonal antibody, a protein activity protecting agent, and proper auxiliary material, wherein the fusion protein of cell growth factor and TAT cell-penetrating peptide or the fusion protein of the cell growth factor, TAT and transferrin receptor monoclonal antibody is an active ingredient. The novel brain targeting preparation disclosed by the invention has excellent performance of breaking through a blood brain barrier, and is specifically targeted to the brain; the defect that single TAT does not have cell selectivity can be overcome; a brain neurons microenvironment is regulated and controlled by the effects of neurotrophy, paracrine and the like, so as to play the roles of preventing and treating the neurodegenerative disease. The novel brain targeting preparation can be prepared into a freeze-drying preparation, a liquid preparation or an adhesive preparation and applied in an intravenous injection or nasal delivery manner.

This invention relates to antagonists of placental growth factor and signalling thereof, pharmaceutical compositions containing such antagonists and the use of such antagonists to prevent bone loss or bone mass and to enhance bone healing including the treatment of conditions which present with low bone mass and/or bone defects in vertebrates, and particularly mammals, including humans.

The invention discloses a screening kit for the seventh chromosome abnormality diseases of a fetus. The screening kit comprises a reagent for detecting the PLGF (placental growth factor) level of the serum or urine of a pregnant woman. The invention further discloses an application for the screening kit for the seventh chromosome abnormality diseases of a fetus in detection for the PLGF level of the serum or urine of a pregnant woman. The kit disclosed by the invention can be used for evaluating whether the seventh chromosome of the fetus is normal or not, and is good in clinical application prospect.

The invention discloses a placental growth factor loaded nano-particle, as well as a preparation method and application thereof. The method comprises the following steps: 1, dispersing an internal water phase (a water solution containing placental growth factors) in an oil phase (an organic solution containing poly(lactic-co-glycolic acid) and an organic solvent) to form colostrum, wherein the polarity of the organic solvent is 4.0-6.0, and the ratio of the internal water phase to the oil phase is (1:3)-(1:10); 2, emulsifying the colostrum in an external water phase (a water solution containing a hydrophilic nonionic surfactant with HLB of 8-18) to form multiple emulsion, wherein the ratio of the oil phase and the external water phase is (1:3)-(1:6); 3, mixing the multiple emulsion and an expanded phase (water or a water solution containing a stabilizing agent), removing the organic solvent and the stabilizing agent, and lyophilizing, wherein the ratio of the external water phase to the expanded phase is (1:5)-(1:15). The placental growth factor loaded nano-particle has a good sustained-release effect, the preparation method can be used for reducing protein degeneration and improving encapsulation efficiency and has a good stability, the organic solvent cannot be dichloromethane or other solvents, and the reaction toxicity can be reduced.

The present invention relates to a method for diagnosing if a pregnant woman suffers from a cardiac dysfunction, comprising the steps of a) measuring the level of a natriuretic peptide in a sample b) measuring the level of placental growth factor and/or sFlt-1 or a variant thereof in a sample, wherein an increased level of a natriuretic peptide and a decreased level of placental growth factor and/or an increased level of sFlt-1 or a variant thereof indicates the presence of a placenta-associated cardiac dysfunction, and wherein an increased level of a natriuretic peptide and a not decreased level of placental growth factor and/or a not increased level of sFlt-1 or a variant thereof indicates the presence of a cardiac dysfunction related to heart disease. The present invention also relates to an array, to an immunological rapid test, to the use of corresponding kits, and to methods for a decision support for the possible treatment of a pregnant woman suffering from a cardiac dysfunction.

This invention relates to methods to reduce or lipid peroxidation and diminish free radical damage in a human, resulting in reduced blood levels of dityrosine, isoprostane, and placental growth factor thus preferably preventing or reducing cardiovascular disease by the in humans administration of compositions comprised of sesame lignans and ‘gamma tocopherol to humans.

The invention discloses a keratinized cell growth factor mutant of high receptor binding force, and also the process for preparing and usage of the mutant. The mutant is prepared by the 102nd mutating amino acid residue of keratinized cell growth factor, that is lycine residue, into glutacid residue, And is prepared by point mutation technique in gene project. The receptor bonding force of mutated keratinized cell growth factor and added value activity of epithelial cell both increases evidently. The mutant can be used to prepare polypeptide pharmaceutical against radiation hurt, ulcer and enteritis, and it also can advance the radiotheraphy index in killing cancer,

The invention relates to the preparation of placental growth factor (PLGF)-comprising therapeutic and cosmetic compositions capable of increasing angiogenesis of the cutaneous, subcutaneous and internal organ connective tissue. Such compositions are suitable for the treatment of pathological or natural states benefiting from the formation or regeneration of new vessels of the cutaneous compartment, such as seleroderma, its various manifestations, skin ageing or loss of hair.

The invention discloses a culture medium good in hematopoietic stem cell adherence. The culture medium comprises an RPMI-1640 culture medium, 5-8mug/L of hyaluronic acid, 3.2-3.8g/L of trehalose, 20-30mg/L of ethanolamine, 0.7-1g/L of potassium bicarbonate, 6-9mug/L of methionine chelate selenium, 2-5mug/L of beta-mercaptoethanol, 2-3g/L of transferrin, 200-260mg/L of stem cell factors, 50-80mg/L of placental growth factors, 30-50mg/L of fibroblast growth factors, 80-100mg/L of glutathione, 80-110mg/L of vitamins and 180-220mg/L of plant extracts. The culture medium is good in cell adherence, rapid in proliferation rate, pathogen-resistant microbial action of the cultural medium is improved, components of animal origin are avoided, residues or pollution cannot be caused, and cost of the culture medium is lowered.

The present invention relates to chemically stable muteins of type 1 Placental Growth Factor (PLGF-1) bearing the substitution or elimination of a cysteine residue from the wild type protein amino acid sequence, their preparation, their therapeutic and cosmetic uses, and pharmaceutical and cosmetic compositions containing said derivatives. The invention likewise relates to the production of antibodies for said derivatives and their use in the diagnosis and treatment of tumoral and non-tumoral pathologies.

The present invention discloses a PLGF (Placental Growth Factor) magnetic particle chemiluminiscence kit and a detection method thereof. The kit comprises a placental growth factor antibody with biotin labeling, streptavidin magnetic particle suspension liquid, a placental growth factor antibody with acridinium ester labeling, a calibration product, cleanout fluid, a diluent, chemiluminiscence pre-excitation liquid A, and chemiluminiscence pre-excitation liquid B. The streptavidin and the biotin have a high-specificity combining capacity, the high-purity antibody of the streptavidin and the biotin labeling is subjected to specific binding through a non covalent bond and has a cascade amplification effect. Besides, an acridinium ester chemiluminescent system is adopted, and the acridinium ester does not need a catalyst and can emit light when being put in a H2O2 solution with no need for a catalytic process and an enhancer. The sensitivity is higher, the reaction time is short, the operation is simple, and the anti-interference performance is high.